The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InZimmer Biomet Holdings, Inc. (NYSE: ZBH) saw its shares climb 4.3% following the announcement of robust financial results for the fourth quarter and full-year 2025. The medical device company reported a significant 10.9% year-over-year increase in Q4 net sales, reaching $2.244 billion. Adjusted diluted earnings per share for the quarter stood at $2.42, exceeding expectations. This strong performance was primarily driven by higher procedure volumes and successful new product adoption. For the full fiscal year, Zimmer Biomet achieved total net sales of $8.232 billion, bolstered by a solid recovery in elective procedures and focused operational execution. The positive figures underscore the company's strong market position and effective strategy.